Known pathogenic LRRK2 mutations produce a protein with increased kinase activity (Alessi and Sammler, 2018; Kluss et al., 2019), raising the possibility that kinase inhibitors may be useful to treat LRRK2-related PD. This evidence concerns the gene LRRK2 and Parkinson disease.